Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.anai.2015.12.023 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Systematic review of omalizumab for refractory clonal and non-clonal mast cell activation syndrome.
Allergy Asthma Proc
January 2025
From the Section of Allergy, Asthma and Immunology, Medicine and Pediatrics, Pennsylvania State University School of Medicine, Hershey, Pennsylvania and.
Patients with mast cell activation syndrome (MCAS) can be refractory to standard antimediator therapy. Alternative treatment options to reduce disease burden and improve quality of life are needed. To compile the evidence that supports the use of omalizumab for patients with refractory MCAS.
View Article and Find Full Text PDFTwo-year follow-up after drug desensitization in mucopolysaccharidosis.
Orphanet J Rare Dis
December 2024
Post Graduate School in Allergology and Internal Medicine "Guido Baccelli", Department of Precision and Regenerative Medicine and Ionian Area-(DiMePRe-J), School of Medicine, Aldo Moro University of Bari, Bari, 70124, Italy.
Background: Mucopolysaccharidosis (MPS) type 1 S and type 2 are rare lysosomal storage disorders characterized by impaired enzyme production, resulting in glycosaminoglycans accumulation within lysosomes. Enzyme Replacement Therapy (ERT) with laronidase and idursulfase are first line treatments, respectively. However, infusion-related hypersensitivity reactions (HR) may lead to ERT discontinuation.
View Article and Find Full Text PDFIntroduction: Emerging evidences have underscored the positive impact of biologics on asthmatic patients. However, there is a pressing need to verify their therapeutic efficacy in children and adolescents with asthma. To address this, we conducted a network meta-analysis (NMA) to evaluate the efficacy and safety of biologics in the asthma management of this demographic.
View Article and Find Full Text PDFSuccessful Treatment of Immune Checkpoint Inhibitor-Induced Bullous Pemphigoid with Omalizumab: A Case Report and Review of the Literature.
Clin Cosmet Investig Dermatol
December 2024
Department of Dermatology, Guangzhou Dermatology Hospital, Guangzhou, 510095 People's Republic of China.
Background: Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment by enhancing the immune system's ability to target cancer cells. However, ICIs can lead to immune-related adverse events (irAEs), including dermatologic manifestations such as bullous pemphigoid (BP).
Objective: To evaluate the efficacy and safety of omalizumab and other biologics in the treatment of ICI-induced refractory bullous pemphigoid and to derive a strategy for selecting biologic treatments for this condition.
Multiomic Integration Analysis for Monitoring Severe Asthma Treated With Mepolizumab or Omalizumab.
Allergy
December 2024
Departamento de Ciencias Médicas Básicas, Facultad de Medicina, Instituto de Medicina Molecular Aplicada - Nemesio Díez (IMMA-ND), Universidad San Pablo-CEU, CEU Universities, Madrid, Spain.
Rationale: Biologics are becoming increasingly important in the management of severe asthma. However, little is known about the systemic immunometabolic consequences of Th2 response blockage.
Objectives: To provide a better immunometabolic understanding of the effects of mepolizumab and omalizumab treatments by identifying potential biomarkers for monitoring.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!